ANVS
Annovis Bio, Inc.NYSEHealthcare$2.35+3.07%ClosedMarket Cap: $46.2M
As of 2026-04-07
Valuation
P/E (TTM)
—
PEG
—
P/B
3.46
P/S
0.00
EV/EBITDA
660.03
DCF Value
$950.27
FCF Yield
-1844.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-159.4%
ROA
-136.9%
ROIC
-170.2%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | NaN% | $-9.7M | $-9.8M | $-0.40 | — |
| FY 2025 | $0.00 | NaN% | $-29.7M | $-28.9M | $-1.40 | — |
| Q3 2025 | $0.00 | NaN% | $-7.4M | $-7.3M | $-0.37 | — |
| Q2 2025 | $0.00 | NaN% | $-6.3M | $-6.2M | $-0.32 | — |
| Q1 2025 | $0.00 | NaN% | $-6.3M | $-5.5M | $-0.45 | — |
| Q4 2024 | $0.00 | NaN% | $-6.7M | $-5.9M | $-0.48 | — |
| FY 2024 | $0.00 | NaN% | $-26.7M | $-24.6M | $-2,009.77 | — |
| Q3 2024 | $0.00 | NaN% | $-4.4M | $-12.6M | $-0.97 | — |
| Q2 2024 | $0.00 | NaN% | $-7.8M | $-5.0M | $-0.44 | — |
| Q1 2024 | $0.00 | NaN% | $-7.8M | $-1.1M | $-0.10 | — |
| Q4 2023 | $0.00 | NaN% | $-10.4M | $-22.2M | $-2.33 | — |
| FY 2023 | $0.00 | NaN% | $-45.0M | $-56.2M | $-6.23 | — |